[Clinical application of CT-guided percutaneous targeted argon-helium cryoablation for soft tissue sarcoma].

OBJECTIVE

To evaluate the clinical efficacy of percutaneous targeted argon-helium cryoablation for soft tissue sarcoma and analyze the changes in CT findings and side effects in relation to the treatment.

METHODS

Thirty-two patients with soft tissue sarcoma were treated with CT-guided argon-helium cryoablation.

RESULTS

Three months after the treatment, 52 tumors showed obvious reduction in size with a total complete and partial remission rate of 73.1%. Postoperative CT scanning displayed low-density local necrosis in the tumors after cryotherapy, and consolidation of the lesions was observed at 3 months and lesion disappearance at 1 year after the therapy. The complications included pneumothorax, coughing, hemoptysis, fever, and slight elevation of aminotransferase.

CONCLUSION

CT-guided percutaneous targeted argon-helium cryoablation is safe and effective for lung cancer with minimal invasions.